Bicycle Therapeutics (BCYC) Reiterated at Market Outperform by Citizens

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $12.00 price target on Bicycle Therapeutics (NASDAQ: BCYC).

The analyst commented, "We reiterate our Market Outperform rating for Bicycle Therapeutics and our price target of $12 based on a discounted EPS and revenue multiple analysis. Yesterday, Bicycle provided updated guidance and strategic priorities for 2026 (FIGURE 1), including dose selection in the pivotal Duravelo-2 study in mUC is on track for 1Q26 after speaking with regulatory agencies. The company also provided guidance on zelenectide pevedotin (zele) in NECTIN-4 amplified BC, BT7480 and BT5528 (NECTIN-4 and EphA2 BDCs) in solid tumors and 2L+ mUC, and its Bicycle radioconjugate (BRC) programs, with summary data from each in an updated corporate deck. With the zele pivotal trial enrolling, multiple partnerships secured, and a strong cash position of $648.3MM, we believe Bicycle shares provide upside from current levels (enterprise value = -$185.8MM)."

For an analyst ratings summary and ratings history on Bicycle Therapeutics click here. For more ratings news on Bicycle Therapeutics click here.

Shares of Bicycle Therapeutics closed at $6.58 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027